Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:PRME NASDAQ:PVLA NASDAQ:PYXS NASDAQ:VIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRMEPrime Medicine$5.33-0.9%$4.74$1.11▼$6.94$717.28M2.652.78 million shs1.81 million shsPVLAPalvella Therapeutics$73.00+2.4%$61.28$11.17▼$77.77$788.55M-0.13203,211 shs125,618 shsPYXSPyxis Oncology$3.46+2.4%$2.26$0.83▼$5.39$209.62M1.33862,622 shs315,778 shsVIRVir Biotechnology$5.98+3.5%$5.32$4.16▼$14.45$802.94M1.271.54 million shs1.41 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRMEPrime Medicine-0.93%-2.20%-4.14%+26.60%+33.58%PVLAPalvella Therapeutics+2.38%-0.21%+24.00%+89.02%+7,299,999,900.00%PYXSPyxis Oncology+2.37%+2.98%+59.45%+176.80%-4.16%VIRVir Biotechnology+3.46%+3.46%+13.69%+5.84%-20.48%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePRMEPrime Medicine$5.33-0.9%$4.74$1.11▼$6.94$717.28M2.652.78 million shs1.81 million shsPVLAPalvella Therapeutics$73.00+2.4%$61.28$11.17▼$77.77$788.55M-0.13203,211 shs125,618 shsPYXSPyxis Oncology$3.46+2.4%$2.26$0.83▼$5.39$209.62M1.33862,622 shs315,778 shsVIRVir Biotechnology$5.98+3.5%$5.32$4.16▼$14.45$802.94M1.271.54 million shs1.41 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePRMEPrime Medicine-0.93%-2.20%-4.14%+26.60%+33.58%PVLAPalvella Therapeutics+2.38%-0.21%+24.00%+89.02%+7,299,999,900.00%PYXSPyxis Oncology+2.37%+2.98%+59.45%+176.80%-4.16%VIRVir Biotechnology+3.46%+3.46%+13.69%+5.84%-20.48%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePRMEPrime Medicine 2.75Moderate Buy$8.9267.29% UpsidePVLAPalvella Therapeutics 2.92Moderate Buy$75.503.42% UpsidePYXSPyxis Oncology 2.71Moderate Buy$7.75123.99% UpsideVIRVir Biotechnology 2.73Moderate Buy$17.30189.30% UpsideCurrent Analyst Ratings BreakdownLatest PYXS, PRME, PVLA, and VIR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025VIRVir BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/13/2025PYXSPyxis OncologyZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/9/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$66.00 ➝ $90.0010/8/2025PVLAPalvella TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PYXSPyxis OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025PVLAPalvella TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$120.0010/2/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $80.009/27/2025PVLAPalvella TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PYXSPyxis OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025VIRVir BiotechnologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/26/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$60.00 ➝ $73.00(Data available from 10/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPRMEPrime Medicine$4.96M144.58N/AN/A$1.37 per share3.89PVLAPalvella Therapeutics$42.81M18.86N/AN/A$5.58 per share13.08PYXSPyxis Oncology$16.15M13.29N/AN/A$2.03 per share1.70VIRVir Biotechnology$74.21M11.19N/AN/A$8.35 per share0.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePRMEPrime Medicine-$198.13M-$1.56N/AN/AN/AN/A-107.87%-74.97%N/APVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)PYXSPyxis Oncology-$77.33M-$1.60N/AN/AN/AN/A-68.56%-52.14%11/11/2025 (Estimated)VIRVir Biotechnology-$521.96M-$4.00N/AN/AN/A-2,895.94%-50.22%-40.78%11/5/2025 (Confirmed)Latest PYXS, PRME, PVLA, and VIR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025PVLAPalvella Therapeutics-$0.85N/AN/AN/AN/AN/A11/11/2025Q3 2025PYXSPyxis Oncology-$0.36N/AN/AN/AN/AN/A11/5/2025Q3 2025VIRVir Biotechnology-$0.70N/AN/AN/A$1.98 millionN/A8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/14/2025Q2 2025PYXSPyxis Oncology-$0.36-$0.30+$0.06-$0.30N/A$2.82 million8/6/2025Q2 2025VIRVir Biotechnology-$0.72-$0.80-$0.08-$0.80$2.38 million$1.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPRMEPrime Medicine$1.4527.00%N/AN/A N/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/AVIRVir BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPRMEPrime MedicineN/A6.506.50PVLAPalvella TherapeuticsN/A7.677.67PYXSPyxis OncologyN/A5.655.65VIRVir BiotechnologyN/A7.017.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPRMEPrime Medicine70.37%PVLAPalvella Therapeutics40.11%PYXSPyxis Oncology39.09%VIRVir Biotechnology65.32%Insider OwnershipCompanyInsider OwnershipPRMEPrime Medicine22.74%PVLAPalvella Therapeutics20.50%PYXSPyxis Oncology10.60%VIRVir Biotechnology16.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePRMEPrime Medicine234134.57 million100.38 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/APYXSPyxis Oncology6062.02 million55.44 millionOptionableVIRVir Biotechnology580138.92 million116.69 millionOptionablePYXS, PRME, PVLA, and VIR HeadlinesRecent News About These CompaniesVir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $690,952.50 in StockOctober 23 at 4:39 PM | marketbeat.comVir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $1,367,317.00 in StockOctober 23 at 4:39 PM | marketbeat.comEndurance (Cayman) Ltd Svf Sells 109,675 Shares of Vir Biotechnology (NASDAQ:VIR) StockOctober 23 at 5:37 AM | insidertrades.comVir Biotechnology (VIR) Projected to Post Quarterly Earnings on ThursdayOctober 23 at 4:19 AM | americanbankingnews.comVir Biotechnology (VIR) to Release Quarterly Earnings on ThursdayOctober 23 at 4:17 AM | marketbeat.comVir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025October 22 at 4:05 PM | businesswire.comNordea Investment Management AB Boosts Stock Position in Vir Biotechnology, Inc. $VIROctober 22 at 4:21 AM | marketbeat.comScientists Discover Antibody that Blocks 98% of HIV StrainsOctober 20, 2025 | msn.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by BrokeragesOctober 20, 2025 | americanbankingnews.comVir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $78,348.40 in StockOctober 18, 2025 | marketbeat.comInsider Selling: Vir Biotechnology (NASDAQ:VIR) Major Shareholder Sells 16,671 Shares of StockOctober 18, 2025 | marketbeat.comEndurance (Cayman) Ltd Svf Sells 12,844 Shares of Vir Biotechnology (NASDAQ:VIR) StockOctober 18, 2025 | insidertrades.comAberdeen Group plc Acquires 313,699 Shares of Vir Biotechnology, Inc. $VIROctober 17, 2025 | marketbeat.comVir Biotechnology (VIR) Gets a Buy from H.C. WainwrightOctober 16, 2025 | theglobeandmail.comWeiss Ratings Reaffirms "Sell (D-)" Rating for Vir Biotechnology (NASDAQ:VIR)October 16, 2025 | americanbankingnews.comEndurance (Cayman) Ltd Svf Sells 2,300 Shares of Vir Biotechnology (NASDAQ:VIR) StockOctober 15, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $1,529,228.40 in StockOctober 15, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 15, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Major Shareholder Sells $13,984.00 in StockOctober 15, 2025 | insidertrades.comVir Biotechnology (NASDAQ:VIR) Given "Sell (D-)" Rating at Weiss RatingsOctober 14, 2025 | marketbeat.comEndurance (Cayman) Ltd Svf Sells 72,133 Shares of Vir Biotechnology (NASDAQ:VIR) StockOctober 10, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePYXS, PRME, PVLA, and VIR Company DescriptionsPrime Medicine NYSE:PRME$5.33 -0.05 (-0.93%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.45 +0.12 (+2.33%) As of 10/24/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.Palvella Therapeutics NASDAQ:PVLA$73.00 +1.70 (+2.38%) As of 10/24/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Pyxis Oncology NASDAQ:PYXS$3.46 +0.08 (+2.37%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$3.44 -0.02 (-0.72%) As of 10/24/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Vir Biotechnology NASDAQ:VIR$5.98 +0.20 (+3.46%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$5.98 -0.01 (-0.08%) As of 10/24/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
